Skip to main content

Atara Biotherapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 28, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 28, 2024

ATRA$8.10-1.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Power of Attorney (included on signature page)

SIGNA TURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Thousand Oaks, State of California, on the 28 th day of March, 2024.

Atara Biotherapeutics, Inc.
By:/s/ Pascal Touchon
Pascal Touchon
President and Chief Executive Officer

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Pascal Touchon and Eric Hyllengren, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Pascal Touchon
Pascal TouchonPresident, Chief Executive Officer and Director (Principal Executive Officer)March 28, 2024
/s/ Eric Hyllengren
Eric HyllengrenChief Financial Officer (Duly Authorized Officer and Principle Financial and Accounting Officer)March 28, 2024
/s/ Carol G. Gallagher
Carol G. Gallagher, Pharm. D.Director, ChairMarch 28, 2024
/s/ Eric L. Dobmeier
Eric L. DobmeierDirectorMarch 28, 2024
/s/ Matthew K. Fust
Matthew K. FustDirectorMarch 28, 2024
/s/ William K. Heiden
William K. HeidenDirectorMarch 28, 2024
/s/ Ameet Mallik
Ameet MallikDirectorMarch 28, 2024
Maria Grazia Roncarolo, M.D.Director
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.